Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 5;12:708111. doi: 10.3389/fendo.2021.708111

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Rai, Das, Mukherjee, Dhandapani, Tripathi, Ahuja, Radotra and Dutta

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Overexpression of pEGFR T693 in recurrent NFPAs. Immunohistochemistry of pEGFR T693 showed overexpression in recurrent NFPAs (B, E, H, K) as compared to non-recurrent NFPAs (A, D, G, J). pEGFR T693 showed strong nuclear positivity (brown) marked by black arrows. Breast cancer (C) and cervical cancer (F) were used as the positive controls. No staining was observed in the negative control (I) and normal pituitary (L). Western blots of representative tumor samples are depicted in (M). The h-score (product of the number of cells with positive staining and staining intensity) showed statistically significant overexpression of pEGFR T693 in recurrent NFPAs as compared to non-recurrent (p < 0.0001) (N). Quantification of the blots (O) show overexpression of pEGFR T693 in representative tumor samples of 18 recurrent NFPAs as compared to 18 non-recurrent ones. Magnification 400x. ****highly significant.